Pharming PHAR
NASDAQ PHAR
$9.65 -0.10 (-1.03%)
As of: Oct 21, 2026 · 2:25 PM EDT

Pharming (PHAR) EV to EBIT (2021 - 2026)

Updated

Pharming's EV to EBIT was 111.63 in Q2 2026, down 82.0% from 621.58 a year earlier but up 87.0% from the prior quarter.

Analysis

Pharming (PHAR) EV to EBIT (2021 - 2026) Analysis & Trends

On a trailing twelve-month basis, Pharming's EV to EBIT was 19.79 through Jun 30, 2026, down 73.2% year-over-year; for FY2025, it was 39.66.

  • In earlier years, EV to EBIT was 18.19 in FY2022 (-100.0%) and 44325.73 in FY2021.
  • Quarterly EV to EBIT has moved between 5.79 (Q3 2021) and 684.99 (Q4 2021) over five years.
  • Per Business Quant data, PHAR's EV to EBIT in the three quarters before Q2 2026 was 59.71 (Q1 2026), 81.31 (Q4 2025) and 65.08 (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,136.97 Bn 1,105.55 Bn 19.71 Bn
2 Johnson & Johnson 619.72 Bn 538.25 Bn 17.26 Bn
3 AbbVie 503.40 Bn 476.52 Bn 12.70 Bn
4 Merck 370.15 Bn 324.53 Bn 12.21 Bn
5 Novartis Ag 298.64 Bn 262.63 Bn 11.24 Bn
6 Astrazeneca 261.07 Bn 234.76 Bn 12.86 Bn
7 Amgen 237.00 Bn 192.40 Bn 7.24 Bn
8 Gilead Sciences 191.24 Bn 165.43 Bn 6.22 Bn
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn
10 Pharming 664.67 Mn -129.70 Mn 141.47 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 111.63
Mar 31, 2026 59.71
Dec 31, 2025 84.15
Sep 30, 2025 65.08
Jun 30, 2025 621.58
Mar 31, 2023 403.74
Dec 31, 2022 28.39
Sep 30, 2022 14.60
Jun 30, 2022 11.06
Mar 31, 2022 14.43
Dec 31, 2021 12.61
Sep 30, 2021 12.43
Jun 30, 2021 9.21
API Access

Pharming EV to EBIT API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ev-to-ebit&ticker=PHAR&period=max&api_key=YOUR_API_KEY